Ignite Creation Date:
2024-05-05 @ 11:34 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00085358
Status:
COMPLETED
Last Update Posted:
2019-07-22
First Post:
2004-06-10
Brief Title:
Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel Carboplatin and Paclitaxel in Treating Patients With Stage II Stage III or Stage IV Ovarian Epithelial Fallopian Tube or Primary Peritoneal Cavity Carcinoma Cancer
Sponsor:
National Cancer Institute NCI
Organization:
National Cancer Institute NCI
Study Overview
Official Title:
A Phase I Trial of Intravenous Paclitaxel Intraperitoneal Carboplatin and Intraperitoneal Paclitaxel or Intravenous Docetaxel Intraperitoneal Carboplatin and Intraperitoneal Paclitaxel or Intravenous Paclitaxel Intraperitoneal Carboplatin Intraperitoneal Paclitaxel and CTEP-Supplied Agent Bevacizumab NSC 704865 IND 7921 in Patients With Previously Untreated Ovarian Fallopian Tube or Primary Peritoneal Carcinoma
Status:
COMPLETED
Status Verified Date:
2019-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This phase I trial is studying the side effects and best dose of intraperitoneal infusions of carboplatin when given together with intravenous infusions of either docetaxel or paclitaxel followed by intraperitoneal paclitaxel in treating patients with stage II stage III or stage IV ovarian epithelial fallopian tube or primary peritoneal cavity carcinoma cancer Drugs used in chemotherapy such as carboplatin docetaxel and paclitaxel work in different ways to stop tumor cells from dividing so they stop growing or die Combining more than one drug and giving them in different ways may kill more tumor cells
Detailed Description:
OBJECTIVES
I Determine the maximum tolerated dose MTD of intraperitoneal IP carboplatin when given in combination with IV paclitaxel followed by IP paclitaxel in patients with stage III or IV ovarian epithelial fallopian tube or primary peritoneal cavity carcinoma
II Determine the MTD of IP carboplatin and IV docetaxel when given in combination with IP paclitaxel in these patients
III To determine the feasibility of the combination of IV paclitaxel IP carboplatin and IV bevacizumab on day one followed by IP paclitaxel on day eight Part C Only
IV Determine the dose-limiting toxic effects and complications in patients treated with these regimens
V Evaluate the neurotoxicity of this regimen at each cycle using the FACTGOG-NTX4 assessment tool to determine dose reduction in these patients
VI Evaluate the techniques used for intraperitoneal catheter placement surgical procedures and reporting of outcomes in these patients
OUTLINE This is a multicenter dose-escalation study of intraperitoneal IP carboplatin
Patients in the dose-escalation phase are not eligible to enter the feasibility phase
DOSE-ESCALATION PHASE PART A or PART B Patients receive IP carboplatin on day 1 and paclitaxel IV over 3 hour part A or docetaxel IV over 1 hour Part B on day 1 and IP paclitaxel on day 8 Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity
FEASIBILITY PHASE PART C Patients receive IP carboplatin on day 1 paclitaxel IV on day 1 and IP paclitaxel on day 8 in course 1 as in part A dose-escalation phase Beginning in course 2 and all subsequent courses patients receive IP carboplatin on day 1 IV paclitaxel on day 1 and IP paclitaxel on day 8 as in the dose-escalation phase and bevacizumab IV over 30-90 minutes on day 1 Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity
Patients are followed every 3 months for 1 year
I Determine the maximum tolerated dose MTD of intraperitoneal IP carboplatin when given in combination with IV paclitaxel followed by IP paclitaxel in patients with stage III or IV ovarian epithelial fallopian tube or primary peritoneal cavity carcinoma
II Determine the MTD of IP carboplatin and IV docetaxel when given in combination with IP paclitaxel in these patients
III To determine the feasibility of the combination of IV paclitaxel IP carboplatin and IV bevacizumab on day one followed by IP paclitaxel on day eight Part C Only
IV Determine the dose-limiting toxic effects and complications in patients treated with these regimens
V Evaluate the neurotoxicity of this regimen at each cycle using the FACTGOG-NTX4 assessment tool to determine dose reduction in these patients
VI Evaluate the techniques used for intraperitoneal catheter placement surgical procedures and reporting of outcomes in these patients
OUTLINE This is a multicenter dose-escalation study of intraperitoneal IP carboplatin
Patients in the dose-escalation phase are not eligible to enter the feasibility phase
DOSE-ESCALATION PHASE PART A or PART B Patients receive IP carboplatin on day 1 and paclitaxel IV over 3 hour part A or docetaxel IV over 1 hour Part B on day 1 and IP paclitaxel on day 8 Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity
FEASIBILITY PHASE PART C Patients receive IP carboplatin on day 1 paclitaxel IV on day 1 and IP paclitaxel on day 8 in course 1 as in part A dose-escalation phase Beginning in course 2 and all subsequent courses patients receive IP carboplatin on day 1 IV paclitaxel on day 1 and IP paclitaxel on day 8 as in the dose-escalation phase and bevacizumab IV over 30-90 minutes on day 1 Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity
Patients are followed every 3 months for 1 year
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| GOG-9916 | None | None | None |
| U10CA027469 | NIH | None | httpsreporternihgovquickSearchU10CA027469 |